The loss ofgonadal negative feedback at menopause, resulting in peak concentrations of FSH andLH at the age when the incidence of ovarian cancer climbs dramatically, providessupport for the gonadotropin hypothesis [6] and LH levels have been reportedto be elevated in BRCA1 mutation carriers in the follicular phase compared withnon-carriers, suggesting that high levels of LH may contribute to BRCA-associatedincreased risk of ovarian cancer [7]. The gene discussed is BRD2; the disease is ovarian cancer.